Medical News

RSS

Engineered protein shown effective in patients with severe von Willebrand disease

The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial.

4 Aug 2015

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

4 Aug 2015

New big data collaboration aims to improve care management for diabetes, mental health

Duke-NUS Graduate Medical School Singapore and Holmusk, a global tele-health platform, have recently announced a collaboration to further the potential of big data in healthcare. Big data refers to very large, unstructured and diverse datasets that cannot be managed using conventional methods. In healthcare, big data and analytics allow us to discover patterns that would not be found otherwise, and make predictions about disease. This has the potential to improve care and lower costs.

4 Aug 2015

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers.

3 Aug 2015

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16").

3 Aug 2015

NurseWise moves to new, larger clinical care center in El Paso

NurseWise, a national multilingual nurse advice and health education provider, has moved its El Paso Clinical Care Center operations into a larger space to accommodate the company's continued growth and commitment to increasing the number of individuals it serves.

3 Aug 2015

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

3 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

15th Annual Geriatric Health Care Symposium now open for registration

Registration is now open for the 15th Annual Geriatric Health Care Symposium, "Maximizing Independence for Optimal Aging," presented by the University of Louisville Institute for Sustainable Health & Optimal Aging.

3 Aug 2015

Illinois Health and Science acquires IBA Molecular North America

IBA Molecular, a global leader in the manufacture and distribution of radiopharmaceuticals, announced today the completion of the previously announced sale of its US operations, IBA Molecular North America, Inc., to Illinois Health and Science (IHS), a non-profit healthcare system based in Decatur, Illinois.

3 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

3 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

Encision announces financial results for Q1 fiscal year 2016

Encision Inc., a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 first quarter that ended June 30, 2015.

3 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively.

3 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Medical News

Engineered protein shown effective in patients with severe von Willebrand disease

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

New big data collaboration aims to improve care management for diabetes, mental health

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

NurseWise moves to new, larger clinical care center in El Paso

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Array Biopharma reports strong fourth quarter and full year 2015 financial results

15th Annual Geriatric Health Care Symposium now open for registration

Illinois Health and Science acquires IBA Molecular North America

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Shire acquires Foresight Biotherapeutics for $300 million

Encision announces financial results for Q1 fiscal year 2016

Omeros receives EC approval to market Omidria in EU and other European countries

Soligenix signs $10M equity purchase agreement with accredited institutional investors

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

RNA-binding protein ROQUIN regulates response to DNA damage

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News